Nkeji 2 Nnwale Clinical of Retatrutide, Hormone Triple-Receptor Agonist, maka ọgwụgwọ oke ibu.

Ndabere na Nhazi Ọmụmụ

Retatrutide (LY3437943) bụ ọgwụ ọhụrụ otu-peptide na-arụ ọrụ.atọ anabata n'out ogeGIP, GLP-1, na glucagon. Iji nyochaa ịdị irè ya na nchekwa ya na ndị nwere oke ibu mana enweghị ọrịa shuga, a na-eme usoro 2, randomized, kpuru ìsì abụọ, na-achịkwa placebo (NCT04881760). Ngụkọta nke338 sonyerena BMI ≥30, ma ọ bụ ≥27 nwere opekata mpe otu nsogbu metụtara ịdị arọ, bụ nke a na-ahaziri iji nweta placebo ma ọ bụ retatrutide (1 mg, 4 mg nwere usoro titration abụọ, 8 mg nwere usoro titration abụọ, ma ọ bụ 12 mg) na-enye otu ugboro kwa izu site na ntụtụ subcutaneous maka izu 48. Nkeisi njedebebụ mgbanwe pasentị na ịdị arọ ahụ na izu 24, yana njedebe nke abụọ gụnyere mgbanwe ịdị arọ na izu 48 yana ọnụ ụzọ mwepu ibu (≥5%, ≥10%, ≥15%).

Nsonaazụ igodo

• Izu 24: Opekempe-squares pụtara pasent mgbanwe na arọ ahụ n'ihe metụtara ntọala bụ

  • Ebe nchekwa: -1.6%

  • 1 mg: -7.2%

  • 4 mg (njikọ): -12.9%

  • 8 mg (njikọ): -17.3%

  • 12 mg: -17.5%

• Izu 48: Pasent mgbanwe na arọ ahụ bụ

  • Ebe nchekwa: -2.1%

  • 1 mg: -8.7%

  • 4 mg (njikọ): -17.1%

  • 8 mg (njikọ): -22.8%

  • 12 mg: -24.2%

N'ime izu 48, ọnụ ọgụgụ ndị sonyere na-enweta ọnụ ụzọ mbelata ịdị arọ n'ụlọ ọgwụ dị ịrịba ama:

• ≥5% ọnwụ: 27% nwere placebo vs. 92-100% n'ime otu nọ n'ọrụ

• ≥10%: 9% nwere placebo vs. 73-93% n'ime otu nọ n'ọrụ

• ≥15%: 2% nwere placebo vs. 55-83% na otu nọ n'ọrụ

N'ime otu 12 mg, ruo26% nke ndị sonyere tụfuru ≥30% nke ịdị arọ ha, nnukwu mbelata ibu dị ka ịwa ahụ bariatric.

Nchekwa
Ihe ọjọọ kachasị emetụta bụ eriri afọ (ọgbụgbọ, ọgbụgbọ, afọ ọsịsa), n'ozuzu ya dị nro ma na-agafeghị oke na nke metụtara dose. Obere mmalite doses (2 mg titration) belatara ihe omume ndị a. A hụrụ mmụba metụtara dose na ọnụọgụ obi, na-arị elu na izu 24, wee na-agbada. Ọnụego nkwụsịtụ sitere na 6-16% gafee otu ndị na-arụ ọrụ, dịtụ elu karịa placebo.

Mkpebi
N'ime ndị okenye nwere oke ibu na-enweghị ọrịa shuga, a na-emepụta retatrutide subcutaneous kwa izu maka izu 48Mbelata dị ukwuu, dabere na dose na ịdị arọ ahụ(ihe ruru ~ 24% pụtara ọnwụ na oke dose), yana mmụba na akara cardiometabolic. Ihe omume ọjọọ nke eriri afọ na-abụkarị nke a na-ejikwa titration. Nchọpụta nke usoro 2 ndị a na-atụ aro retatrutide nwere ike ịnọchite anya akara ọgwụgwọ ọhụrụ maka oke ibu, na-eche nkwenye na nnwale 3 ogologo oge.